CompuMed, Inc (CMPD) Fair Value & Analysis

Healthcare · US · Market cap $7.8M

A solid business, screening 52% undervalued on our models.

What matters now

• The price is below even our cautious bear case ($7.01). The market is more pessimistic than our downside scenario.
• Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

60‑month range $1.50 – $10.00 · fair‑value band $7.01 – $11.20 · the $6.00 price screens below the $9.11 fair value. Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

CompuMed, Inc (CMPD) currently trades at $6.00, while our model-based Fair Value estimate is $9.11, implying the stock looks roughly 51.8% undervalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, CompuMed, Inc generated revenue of $1.7M at a net margin of -2.4%. Revenue grew 1.4% year over year. It earns a return on equity of -30.4%. Fundamentals as of Jul 15, 2026

Our scenario range runs from $7.01 (bear case) to $11.20 (bull case); at $6.00, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 208% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -53% fair-value upside, at 52%, CMPD screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Asset-Based ($1.61) versus Growth DCF ($1.43). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

CompuMed, Inc. provides diagnostic telemedicine solutions in the United States. It offers a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including echocardiogram, ECG/EKG, nuclear cardiology, cardiac CT and MRI, MUGA scan, cardiac catheterization, pediatric, stress testing, and holter/event monitor; …

Full company description

CompuMed, Inc. provides diagnostic telemedicine solutions in the United States. It offers a suite of telecardiology services and diagnostic exam interpretations for pediatric and adult patients, including echocardiogram, ECG/EKG, nuclear cardiology, cardiac CT and MRI, MUGA scan, cardiac catheterization, pediatric, stress testing, and holter/event monitor; and teleradiology reading and interpretation services, such as X-ray, ultrasound, chest CT, MRI, measurement, and on demand consult. The company also provides telepathology reading and interpretation services for liver, renal/kidney, pancreas, and tissue; and pulmonology reading and interpretation services comprising bronchoscopy, 3D rendering, measurement, and lung management. In addition, it provides support services; and operates CompuMed, a cloud-based portal that allows to view, manage, and share your case data. The company serves organ donation/transplant, correctional healthcare, hospitals, and rural hospital telemedicine medicines. CompuMed, Inc. was incorporated in 1986 and is headquartered in Los Angeles, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

CompuMed, Inc reported revenue of $7.5M in FY2025 versus $6.3M in FY2021, a compound +4.5%/yr. Reported net income was −$64.2K in FY2025.

Watch CMPD: get an alert when its fair value changes →

Peer Group

Health Information Services · 125 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Health Information Services median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.